Japan-UK firm is looking to build on a combination of internal and external assets to pursue a more independent business development path in Japan and beyond, in parallel with ongoing discovery and development collaborations.

Qpex licenses rights to its antibiotic portfolio in China to Brii Biosciences. Moberg and DongKoo partner on commercialization of onychomycosis therapy in Korea.

Market expansion services provider has its headquarters in Switzerland but a long history and most of its business in Southeast Asia, where the global head of its Business Unit Healthcare tells Scrip it continues to build a broad range of services based around knowledge and penetration of local markets.

Boryung Pharm's original antihypertensive drug continues to increase its global presence, this time through the biggest license agreement so far for the product, with Zuellig Pharma, which will enable the South Korean pharma to sell fimasartan in the rapidly growing Southeast Asian markets.